UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                  FORM 10-QSB/A

            [X] Quarterly Report Pursuant to Section 13 or 15(d) of the
                          Securities Exchange Act of 1934
                   For the quarterly period ended March 31, 2002

                                       or
             [ ] Transition Report Pursuant to Section 13 or 15 (d) of
                        the Securities Exchange Act of 1934

                           Commission file No. 0-26809

                       SHARPS ELIMINATION TECHNOLOGIES, INC.
               (Exact name of registrant as specified in its charter)

                  Delaware                          91-1962104
         (State of incorporation)      (I.R.S. Employer Identification Number)


                         Suite 310, The Pemberton Bldg.
                            744 West Hastings Street
                              Vancouver, B.C. V6C 1A5
                (address of principal executive offices) (Zip Code)

                                  (604) 646-8888
                (Registrant's telephone number, including area code)

                                ASPI EUROPE, INC.
                              312 North 13th Street
                            Oxford, Mississippi 38655
           Former name and former address if changed since last report

   Indicate by check mark whether the registrant: (1) has filed all reports
   required to be filed by Section 13 or 15 (d) of the Securities Exchange Act
   of 1934 during the proceeding 12 months (or for such shorter period that the
   registrant was required to file such reports), and (2) has been subject to
   such filing requirements for the past 90 days.

                                  YES [X] NO [ ]

As of June 18, 2002, the Company had 24,093,147 issued and outstanding shares of
common stock, which includes 15,800,000 common shares contingently issued in
connection with the March 25, 2002 acquisition explained in Note 1 to the
financial statements filed with this report.


<PAGE>




                        PART I -- FINANCIAL INFORMATION

ITEM 1.      FINANCIAL STATEMENTS

                       SHARPS ELIMINATION TECHNOLOGIES INC.
                           (FORMERLY ASPI EUROPE, INC.)
                      CONSOLIDATED CONDENSED BALANCE SHEETS

                                                         March 31,     December
                                                           2002        31, 2001
                                                        (Unaudited)
--------------------------------------------------------------------------------

ASSETS
Current Assets
  Cash and cash equivalents                             $   24,976    $     271
--------------------------------------------------------------------------------
Total Current Assets                                        24,976          271

Advances to related party                                   75,000           --
                                                       -------------------------
Total Assets                                            $   99,976     $    271
--------------------------------------------------------------------------------

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
  Accounts payable                                      $   86,399    $ 195,324
   Due to related parties                                       --       93,888
   Loan payable                                             96,765      145,209
   Convertible note payable                                      -      146,687
--------------------------------------------------------------------------------
Total Current Liabilities                                  183,164      581,108

Total Liabilities                                          183,164      581,108
--------------------------------------------------------------------------------

Stockholders' Deficit
  Common stock, $0.001 par value; 50,000,000 shares
   authorized,                                                           18,213
    8,205,008 and 18,213,147 issued and outstanding          8,205
  Additional paid-in capital                             5,026,956    4,525,087
  Accumulated deficit                                   (5,118,349)  (5,124,137)
--------------------------------------------------------------------------------

Total Stockholders' Deficit                                (83,188)    (580,837)
--------------------------------------------------------------------------------

Total Liabilities and Stockholders' Deficit           $     99,976  $       271
--------------------------------------------------------------------------------

      See accompanying notes to consolidated condensed financial statements.


<PAGE>



                       SHARPS ELIMINATION TECHNOLOGIES INC.
                           (FORMERLY ASPI EUROPE, INC.)
                  CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
        FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2002 AND MARCH 31, 2001
                                   (Unaudited)


                                              Three Months Ended March 31,
                                              -----------------------------
                                                  2002           2001
---------------------------------------------------------------------------

 OPERATING EXPENSES
  General and administrative                    $  23,370     $       -
  Interest expense, net                             6,311             -
---------------------------------------------------------------------------

 Total operating expenses                          29,681             -
---------------------------------------------------------------------------

 Loss from continuing operations                   (29,681)           -

 DISCONTINUED OPERATIONS
  Loss from discontinued operations                     -    (1,376,449)
  Gain on settlement of debt                       35,469             -
---------------------------------------------------------------------------

 Net income (loss) from  discontinued
 operations                                        35,469    (1,376,449)
---------------------------------------------------------------------------

 Net income (loss)                               $  5,788   $ (1,376,449)
---------------------------------------------------------------------------

 Net income (loss) per share -
      Continuing operations                     $     Nil     $      -
      Discontinued operations                         Nil        (0.19)
---------------------------------------------------------------------------

   Net income per share - basic and
               diluted                          $     Nil     $   (0.19)
---------------------------------------------------------------------------

 Weighted average number of
   shares of common stock
   outstanding                                 10,395,023     7,192,132
---------------------------------------------------------------------------


      See accompanying notes to consolidated condensed financial statements.

<PAGE>


                       SHARPS ELIMINATION TECHNOLOGIES INC.
                           (FORMERLY ASPI EUROPE, INC.)
             CONSOLIDATED CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT

<TABLE>
<S>                                 <C>        <C>        <C>            <C>           <C>

                                      Common Stock

                                                        Additional
                                                         Paid-in      Accumulated
                                   Shares     Amount     Capital        Deficit        Total
   ------------------------------------------------------------------------------------------

Sharps Elimination
Technologies Inc. (formerly
ASPi Europe, Inc.)

   Balance, December 31, 2001     18,213,147  $18,213  $4,525,087     $(5,124,137)   $(580,837)

   Redemption of exchangeable
     shares                      (10,500,000) (10,500)     10,500               -            -

   Conversion of notes payable        92,058       92      91,966               -       92,058

   Conversion of convertible
     note payable                    149,385      149     149,236               -      149,385

   Conversion of accounts
     payable                         150,418      151     150,267               -      150,418

   Issuance of common stock
     for cash                        100,000      100      99,900               -      100,000

   Net income                              -        -           -           5,788        5,788
   --------------------------------------------------------------------------------------------

   Balance, March 31, 2002
     (Unaudited)                   8,205,008    8,205   5,026,956      (5,118,349)     (83,188)
   --------------------------------------------------------------------------------------------

</TABLE>


      See accompanying notes to consolidated condensed financial statements.






<PAGE>


                       SHARPS ELIMINATION TECHNOLOGIES INC.
                           (FORMERLY ASPI EUROPE, INC.)
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
        FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2002 AND MARCH 31, 2001
                                  (Unaudited )

                                                 Three Months Ended March 31,
                                                    2002              2001
--------------------------------------------------------------------------------

Cash Flows From Operating Activities
  Net income (loss)                             $   5,788         $(1,376,449)
  Adjustments to reconcile net loss to net
   cash provided by (used in) operating
   activities:
   Amortization and depreciation                       --            91,851
   Gain on settlement of debt                      35,469                 -
   Stock based compensation expense                     -           999,332
   Change in assets and liabilities:
     Accounts receivable                                -              (726)
     Due to related party                         (93,888)              306
     Accounts payable                             (68,975)          344,432
            Accrued interest on convertible                               -
note payable                                        2,698
            Accrued interest on loan payable        3,613                 -
            Accrued interest on equipment
financing                                               -             7,515
--------------------------------------------------------------------------------
Net Cash Provided by (Used in) Operating
Activities                                       (115,295)           66,261
--------------------------------------------------------------------------------
Cash Provided by (Used in) Investing
  Activities
    Purchase of furniture and equipment, net            -           (22,124)
--------------------------------------------------------------------------------
Net Cash Provided by (Used in) Investing
  Activities                                           --           (22,124)
--------------------------------------------------------------------------------
Cash Flows From Financing Activities
  Proceeds from issuing common stock              100,000                 -
    Proceeds from loan payable                     40,000                 -
    Proceeds from stock options exercised               -               214
  Repayment of equipment financing                      -           (22,124)
    Change in bank overdrafts                           -             5,826
--------------------------------------------------------------------------------
Net Cash Provided by (Used in) Financing
Activities                                        140,000           (16,084)
--------------------------------------------------------------------------------
Effect of Translation Adjustment on Cash                -           (14,086)
--------------------------------------------------------------------------------
Net Increase in Cash and Cash Equivalents          24,705            13,967
--------------------------------------------------------------------------------
Cash and Cash Equivalents, beginning of
period                                                271             2,437
--------------------------------------------------------------------------------
Cash and Cash Equivalents, end of period        $  24,976         $  16,404
--------------------------------------------------------------------------------
Cash paid during the period for interest        $       -         $   3,097

Non-Cash Investing and Financing Activities:

 Conversion of notes payable to common stock    $ 149,385                 -

 Conversion of loans payable to common stock    $  92,058                 -

 Conversion of accounts payable to common       $ 150,418                 -
  stock

 Purchase of financed furniture and             $       -         $ 140,617
  equipment




     See accompanying notes to consolidated condensed financial statements.


<PAGE>


                       SHARPS ELIMINATION TECHNOLOGIES INC.
                           (FORMERLY ASPI EUROPE, INC).

               NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
                                   (Unaudited)

NOTE 1.     BUSINESS DESCRIPTION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Except where the context indicates otherwise, references in this Quarterly
Report on Form 10-Q to the "Company" refers to the registrant, Sharps
Elimination Technologies, Inc., a Delaware corporation.

The Company was incorporated in the State of Florida on August 17, 1984, under
the name of AIDA Industries, Inc. and on December 19, 2000, redomiciled to the
state of Delaware. From its inception until July 20, 1998, there was no activity
within the Company. On July 20, 1998, the Company amended its Articles of
Incorporation to provide for a thousand to one (1,000:1) stock split and was
quoted on the OTC Bulletin Board. The Company began operations in January of
1999, and on March 24, 1999, the Company changed its name from AIDA Industries,
Inc. to Shopping Sherlock, Inc. On May 5, 2001, the Company changed its name
from Shopping Sherlock, Inc. to ASPi Europe, Inc. and on May 3, 2002 changed its
name to Sharps Elimination Technologies Inc.

On June 11, 2001 and amended on June 29, 2001, the Company executed an
Amalgamation and Re-Organization Agreement (the "Re-Organization Agreement") to
acquire all of the issued and outstanding equity securities of GrowthExperts
Group Inc. ("GrowthExperts") in exchange for up to 10,500,000 shares of common
stock of the Company and the assumption of all options to purchase equity
securities of GrowthExperts. GrowthExperts is an Alberta corporation that
provided outsorced customer relationship management services.

The acquisition of GrowthExperts was treated as a reverse acquisition whereby
the Company was acquired by GrowthExperts, with the unaudited balance sheets
being combined using each company's historical cost basis. The results of
operations include that of both companies from the date of closing the
acquisition, July 9, 2001, forward. The financial statements for the period
prior to the date of acquisition are those of GrowthExperts. The equity section
of the balance sheet and the net loss per share of the Company are retroactively
restated to reflect the effect of the exchange ratio established in the asset
purchase agreement.

On December 5, 2001, due to GrowthExperts' lack of working capital and failure
to meet current minimum obligations, GrowthExperts filed an assignment into
bankruptcy under Canada's Bankruptcy and Insolvency Act. A trustee was named in
the bankruptcy proceedings and took immediate possession of GrowthExperts'
assets and closed all of GrowthExperts' offices.

On January 22, 2002, the Company entered into the Stock Redemption and
Settlement Agreement (the "Redemption Agreement") with Scott Dow and F. Thomas
Winters III under which the parties agreed to a mutual release of liability in
consideration for, among other things, the redemption of 2,944,611 Exchangeable
Shares that Mr. Dow and Mr. Winters owned or had control over, stock options for
300,000 shares of the Company's common stock which Mr. Winters had the right to
purchase and the release of Mr. Dow and Mr. Winters from their personal
guarantees on a $150,000 promissory note issued by the Company to GrowthExperts
on May 1, 2001.



<PAGE>


At a special meeting of GrowthExperts' Exchangeable Shareholders held on January
22, 2002, the Exchangeable Shareholders voted in favor of amending certain
exchange and voting rights attached to their Exchangeable Shares such that the
10,500,000 Exchangeable Shares issued were no longer exchangeable into common
shares of the Company and carried no voting rights.

On February 11, 2002, the Company announced that it entered into a letter of
intent to acquire all of the issued and outstanding equity securities of Sharps
Elimination Technologies Inc. ("SETI") a Delaware corporation based in Oxford,
Mississippi that is focused on the prevention of needlestick injuries through
the use of its exclusive license to develop, manufacture and sell the
Needle-Ease(TM) device. Under the terms of the letter of intent, the Company
intended to acquire all of SETI's outstanding securities in exchange for
15,800,000 shares of common stock of the Company.

On March 22, 2002,  Kelly Fielder was appointed the Chief Executive  Officer and
sole Director of the Company.  Mr. Fielder is also the Chief  Executive  Officer
and Director of SETI.

On March 25, 2002, the Company acquired all of the issued and outstanding equity
securities of SETI in exchange for 15,800,000 contingent shares of the Company's
common stock. The shares of the Company's common stock issued to SETI's former
shareholders are subject to earnout conditions imposed mutually by the Company
and the former shareholders of SETI. The 15,800,000 contingent shares of common
stock are to be placed with an escrow agent and will be released if, among other
conditions, SETI sells at least 6,000 Model 3500P devices by March 25, 2003.
Should SETI not meet the conditions to release the 15,800,000 contingent shares
of common stock, the 15,800,000 contingent shares will be returned to the
Company for cancellation and all the shares of SETI received by the Company in
this transaction will be returned to the former SETI shareholders.

Since the shares issued in connection with the acquisition of SETI may be
returned to the Company under certain conditions, for financial reporting
purposes the acquisition of SETI will not be recognized, and the accounts of
SETI will not be consolidated with the accounts of the Company, until all
conditions relating to the issuance of the shares have been satisfied.

As of March 31, 2002 SETI did not have any revenues. As of March 31, 2002 SETI's
assets, liabilities and shareholders' deficit (unaudited) were:

            Assets                   $    17,812
            Liabilities              $ 1,034,545
            Shareholders' Deficit    $(1,016,733)

The consolidated condensed financial statements of the Company include the
accounts of its subsidiaries (with the exception of SETI) after elimination of
intercompany balances and transactions.

Accounting Estimates - The Company's financial statements are prepared in
conformity with accounting principles generally accepted in the United States of
America which requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements, and the reported
amounts of revenue and expenses during the reporting period. Actual results
could differ from the estimates.

Cash and Cash Equivalents - The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash
equivalents. Cash and cash equivalents consist primarily of deposits at
federally insured financial institutions.



<PAGE>


Long-Lived Assets - In accordance with Statement of Financial Accounting
Standards ("SFAS") No. 121, "Accounting for the Impairment of Long-Lived Assets
and for Long-Lived Assets to be Disposed Of," the Company records impairment
losses on long-lived assets used in operations whenever events or circumstances
indicate that the carrying amount of an asset may not be recoverable based on
undiscounted cash flows. An impairment is recognized to the extent that the sum
of undiscounted estimated future cash flows expected to result from use of the
assets is less than the carrying value.

Fair Value of Financial Instruments - The Company's financial instruments
include cash, accounts receivable and notes payable, which due to the nature and
duration of the financial instruments, approximates their fair value.

Stock-Based Compensation - SFAS No. 123, "Accounting for Stock-based
Compensation," establishes a fair value method of accounting for stock-based
compensation plans and for transactions in which a company acquires goods or
services from non-employees in exchange for equity instruments. SFAS 123 also
gives the option to account for stock-based employee compensation in accordance
with Accounting Principles Board Opinion ("APB") No. 25, "Accounting for Stock
Issued to Employees," or SFAS 123. The Company elected to follow APB 25 which
measures compensation cost for employee stock options as the excess, if any, of
the fair market price of the Company's stock at the measurement date over the
amount an employee must pay to acquire the Company's stock by exercise of the
stock options granted.

Foreign Currency - Exchange gains and losses from holding foreign currencies and
having liabilities in foreign currencies are included in the consolidated
condensed statements of operations.

Recent Accounting Pronouncements - In June 2001, the FASB approved for issuance
SFAS 141, Business Combinations. This standard eliminates the pooling method of
accounting for business combinations initiated after June 30, 2001. In addition,
SFAS 141 addresses the accounting for intangible assets and goodwill acquired in
a business combination. This portion of SFAS 141 is effective for business
combinations completed after June 30, 2001. The Company does not expect SFAS 141
to have a material effect on the Company's financial position or results of
operations.

In June 2001, the FASB approved for issuance SFAS 142, Goodwill and Intangible
Assets, which revises the accounting for purchased goodwill and intangible
assets. Under SFAS 142, goodwill and intangible assets with indefinite lives
will no longer be amortized, but will be tested for impairment annually and also
in the event of an impairment indicator. SFAS 142 is effective for the fiscal
years beginning after December 15, 2001, with early adoption permitted for
companies with fiscal years beginning after March 15, 2001 if their first
quarter financial statements have not been previously issued. The Company does
not expect SFAS 142 to have a material effect on the Company's financial
position or results of operations.

In June 2001, the FASB issued SFAS 143, Accounting for Asset Retirement
Obligations, which is effective for fiscal years beginning after June 15, 2002.
SFAS 143 addresses the financial accounting and reporting obligations and
retirement costs related to the retirement of tangible long-lived assets. The
Company does not expect that the adoption of SFAS 143 will have a significant
impact on its financial position and results of operations.

In August 2001, the FASB issued SFAS 144, Accounting for the Impairment of
Disposal of Long-Lived Assets, which is effective for the fiscal years beginning
after December 15, 2001. SFAS 144 supersedes SFAS 121, Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of, and
the accounting and reporting provisions relating to the disposal of a segment of
a business of Accounting Principles Board Opinion No. 30. The Company does not
expect that the adoption of SFAS 144 will have a significant impact on its
financial position and results of operations.



<PAGE>


NOTE 2.     BASIS OF PRESENTATION

The accompanying consolidated condensed financial statements of the Company are
unaudited and include, in the opinion of management, all normal recurring
adjustments necessary to present fairly the consolidated condensed balance sheet
as of March 31, 2002, and the related statements of operations, stockholders'
deficit and cash flows for the periods presented. Certain information and
footnote disclosures normally included in financial statements prepared in
accordance with accounting principles generally accepted in the United States of
America have been condensed or omitted pursuant to the rules and regulations of
the Securities and Exchange Commission (the "Commission"). These consolidated
condensed financial statements should be read in conjunction with the Company's
fiscal 2001 audited consolidated financial statements and the related notes
thereto included in the Company's Form 10-K filed with the Commission on April
19, 2002.

NOTE 3.     GOING CONCERN

The Company has never generated profits, and there is no assurance that, in the
future, the Company will be profitable. The Company expects to continue to incur
operating losses until significant funding can be obtained. In addition, over
the next twelve months, the Company plans to increase operating expenses in
order to fund the business of SETI.

The Company believes that it has sufficient working capital and access to
additional capital to sustain operations through June 2002. The Company cannot
assure that funds raised in the future will be sufficient to finance the
complete cost of its operations. The Company will require additional funds
before the Company can achieve positive cash flow from operations. The Company
is actively in the process of raising additional capital. The Company cannot
assure that additional financing or additional funds will be available when the
Company needs them or, if available, on terms acceptable to the Company. If
adequate funds are not available, the Company may not be able to continue. Any
additional stock or convertible debt financing which the Company obtains, if
any, could result in substantial dilution to stockholders. The Company currently
has no commitments for any credit facilities such as revolving credit agreements
or lines of credit that could provide additional working capital and substantial
doubt exists regarding the Company's ability to continue as a going concern.

NOTE 4.     DISCONTINUED OPERATIONS

On December 5, 2001, the Company's wholly-owned subsidiary, GrowthExperts, filed
an assignment into bankruptcy, which effectively transferred control of all the
GrowthExperts' assets and obligations to the bankruptcy trustee and ceased all
its operating activities. As a result, the Company has reclassified its prior
year financial statements to present the operating results as a discontinued
operation.

NOTE 5.     NET LOSS PER SHARE

Basic loss per share is computed by dividing net loss by the weighted average
number of common stock outstanding. Per share information for all prior periods
have been retroactively restated to reflect the effect of the exchange ratio
established in the Re-Organization Agreement with GrowthExperts. As of March 31,
2002, the Company had outstanding options to purchase 200,000 shares of common
stock and outstanding warrants to purchase 575,500 shares of common stock which
were not included in the calculation of loss per share as their effect was
anti-dilutive.



<PAGE>


NOTE 6.     LICENSING AGREEMENT

On November 12, 2001, the Company's wholly-owned subsidiary, SETI, entered into
an agreement (the "Licensing Agreement") with Spectrum Meditech Inc.
("Spectrum") to acquire the exclusive license to the Needle-Ease(TM) technology.
The technology includes Spectrum's Patent and pending United States Patents, as
well as blueprints, drawings, specifications, engineering data, engineering
calculations, processes, apparatuses, and parts relating to the Needle-Ease(TM)
product. Included as part of the license are the rights to use the
Needle-Ease(TM) trademarks and tradenames. Under the Licensing Agreement, SETI
is required to pay $300,000 by November 12, 2002 and subject to a royalty of
$3.25 per unit sold or sub-licensed with a minimum commitment of $100,000 per
annum. To date, SETI has paid $25,000 of the required payment.

NOTE 7.     CONVERTIBLE NOTE PAYABLE

On May 17, 2000, the Company issued $125,000 of convertible subordinated debt to
a third party. The note had a maturity date of August 31, 2001 with interest
accruing at the rate of 10% per annum through July 31, 2001 and 12.5%
thereafter. The note is convertible into common stock at a price equal to 80% of
the trading price of the common stock on the date such advance is converted. On
March 4, 2002, the note and related accrued interest was converted into 149,385
shares of the Company's common stock at an agreed-upon price of $1.00 per share.
On the conversion date, 80% of the trading price of the common stock was $1.10.

NOTE 8.     LOANS PAYABLE

On January 22, 2001, the Company issued a $50,000 promissory note to an
individual. The note had a maturity date of May 18, 2001 with interest accruing
at the rate of 10% per annum. On August 6, 2001, the note was amended such that
the principal and accrued interest was due October 15, 2001 and the interest
would accrue at 12.5% per annum effective July 31, 2001. On May 1, 2002, the
note and related accrued interest was converted into 57,140 shares of the
Company's common stock.

On August 15, 2001, the Company issued a $50,000 promissory note to a third
party. The note had a maturity date of November 30, 2001 with interest accruing
at the rate of 12% per annum. On March 13, 2002, the note and related accrued
interest was converted into 53,452 shares of the Company's common stock.

On November 2, 2001, the Company issued a $37,000 promissory note to a third
party. The note had a maturity date of November 30, 2001 with interest accruing
at the rate of 12% per annum. On March 15, 2002, the note and related accrued
interest was converted into 38,606 shares of the Company's common stock.

On March 21, 2002, the Company received a short term loan in the amount of
$40,000. On April 9, 2002, the loan was converted into 40,000 shares of the
Company's common stock.

NOTE 9.     DUE TO RELATED PARTY

Amounts due to related parties are comprised of loans and unpaid consulting fees
owing to a director and a company controlled by a director, and are interest
free, unsecured, and have no specified terms of repayment.



<PAGE>


NOTE 10.    STOCKHOLDERS' DEFICIT

On March 25, 2002, the Company sold 100,000 shares of common stock for an
aggregate of $100,000 to an investor. In connection with this sale, the Company
issued one-year warrants to purchase 50,000 shares of common stock at an
exercise price of $1.50 per share and three-year warrants to purchase 50,000
shares of common stock at an exercise price of $2.00 per share. In connection
with this sale, the Company granted the investor certain registration rights
with respect to 100,000 shares of the common stock and the underlying shares to
be issued upon the exercise of the above described warrants.

During the three months ended March 31, 2002, the Company issued 150,418 shares
of common stock to creditors of the Company to extinguish approximately $150,418
in accounts payables. Of these amounts, approximately $95,200 was due to related
parties.

NOTE 11.    COMMITMENTS

Royalties - The Company's wholly-owned subsidiary, SETI, is required to pay a
minimum of $100,000 during the next twelve months for royalties under the
Licensing Agreement. In addition, SETI is required to pay a minimum of $16,666
in royalties over the next twelve months to the original patent holders.

Leases - The Company's wholly-owned subsidiary, SETI, currently leases an office
in Oxford, Mississippi. The lease has an expiration date of December 2002.
SETI's future minimum payments under this lease are $6,750 for the year ended
December 31, 2002.

Employment agreements - The Company's wholly-owned subsidiary, SETI has
employment agreements with two executive officers. The agreements provide for
aggregate base compensation of $15,000 monthly.


<PAGE>


                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                     FINANCIAL CONDITION AND PLAN OF OPERATION

      The Company was incorporated in 1984. Between 1984 and June 2001 the
Company was involved in several businesses, all of which have been discontinued.

      In June 2001 the Company acquired all of the issued and outstanding equity
securities of GrowthExperts Group Inc. in exchange for 9,750,000 Exchangeable
Shares. Each Exchangeable Shares was exchangeable at any time, at the holders
option, for one share of the Company's common stock. On October 7, 2001, the
former GrowthExperts shareholders were issued an additional 750,000 Exchangeable
Shares due to the Company's failure to meet certain obligations to
GrowthExperts.

      GrowthExperts was formed to provide outsourced sales and customer
relationship management services. On December 5, 2001, GrowthExperts filed
bankruptcy under Canada's Bankruptcy and Insolvency Act due to lack of working
capital. At a special meeting of GrowthExperts' Exchangeable Shareholders held
on January 22, 2002, the Exchangeable Shareholders voted to amend the rights
attached to the Exchangeable Shares such that the 10,500,000 Exchangeable Shares
would no longer be exchangeable into common shares of the Company.

      On March 26, 2002 the Company acquired all of the issued and outstanding
shares of Sharps Elimination Technologies Inc. ("SETI") in exchange for
15,800,000 contingent shares of the Company's common stock. The Agreement
relating to the acquisition of SETI provides that the 15,800,000 contingent
shares of common stock will be returned to the Company and cancelled unless SETI
sells at least 6,000 Needle-Ease devices by March 26, 2003. The 6,000
Needle-Ease devices must be sold at an average price of U.S. $300 per unit and
all sales must be verified by receipt of cash no later than April 26, 2003.

     In April  2002 the  Company  changed  its name from "ASPi  Europe  Inc." to
"Sharps Elimination Technologies Inc."

      The Company's business is now that which is being conducted by SETI and
any reference to the Company, unless otherwise indicated, includes SETI.

      SETI was incorporated in Delaware on September 25, 2001. On November 12,
2001, SETI acquired the exclusive license, subject to a cash payment of $300,000
to develop, manufacture, and sell Needle-Ease(TM), a device used for the safe
disposal of used needles and hypodermic syringes. The danger of needlestick
injuries lies in the transfer of bloodborne diseases as a result of people
accidentally being stuck with a used syringe.

      The Needle-Ease(TM) is a battery operated incineration system that
destroys a range of needles by passing an electric current through the needle
thereby reducing the steel to ashes in a matter of seconds. The electric charge
is generated from a rechargeable sealed lead-acid battery. The contact points of
the device can be touched directly or with a metal object by the operator or
anyone else without the transfer of current (i.e. shock).


<PAGE>


      SETI anticipates that it will begin full-scale marketing of its
Needle-Ease devices in July 2002.

      During the twelve months ending December 31, 2002 the Company anticipates
that its capital requirements will be as follows:

     Licensing fees                 $ 360,000
     Capital expenditures             500,000
     Inventory build-up               697,000
     Accounts receivable build-up     200,000
     Initial marketing plan           200,000
     Working capital                  543,000

                                   $2,500,000

      The Company does not have any bank lines of credit, or any other
traditional financing arrangements. The Company expects to obtain additional
capital through the private sale of the Company's common stock or from
borrowings from private lenders or financial institutions. There can be no
assurance that the Company will be successful in obtaining any additional
capital needed for its operations.


RESULTS OF OPERATIONS

Three Months Ended March 31, 2002

      In June 2001 the Company acquired all of the issued and outstanding equity
securities of GrowthExperts Group Inc., a corporation formed to provide
outsourced sales and customer relationship management services. The acquisition
of GrowthExperts was treated as a reverse acquisition whereby the Company was
acquired by GrowthExperts. The financial statements for the period prior to the
date of acquisition (June 2001) were those of GrowthExperts. On December 5,
2001, GrowthExperts filed bankruptcy under Canada's Bankruptcy and Insolvency
Act due to lack of working capital. As a result of the bankruptcy filing, the
operating results for the three months ended March 31, 2001 are shown as
"Discontinued Operations".

      Since the shares issued in connection with the acquisition of SETI may be
returned to the Company under certain conditions, for financial reporting
purposes the acquisition of SETI will not be recognized, and the accounts of
SETI will not be consolidated with the accounts of the Company, until all
conditions relating to the issuance of the shares have been satisfied.

      During the twelve months ended December 31, 2001, and the three months
ended March 31, 2002, SETI did not sell any Needle-Ease devices. SETI
anticipates that it will begin full-scale marketing of its Needle-Ease devices
in July 2002.


<PAGE>


                                     PART II
                                OTHER INFORMATION

Item 6.       Exhibits and Reports on Form 8-K

(a)  Exhibits

     No exhibits are filed with this report

(b)  Reports on Form 8-K

     During the quarter ending March 31, 2002 the Company filed the following
reports on Form 8-K:

     Report filed 01/04/02 - Disclosed bankruptcy of the Company's subsidiary,
Growth Experts Group Inc.

     Report filed 03/25/02 - Disclosed resignation of officer and director.
Disclosed amendment to terms of Exchangeable Shares issued in connection with
acquisition of Growth Experts Group Inc.

     Report filed 03/25/02 - Disclosed Letter of Intent to acquire Sharps
Elimination Technologies, Inc.



<PAGE>


                                   SIGNATURES

      Pursuant to the requirements of Section 12 of the Securities Exchange Act
of 1934, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized.

                              SHARPS ELIMINATION TECHNOLOGIES, INC.


Date: June 19, 2002           By: /s/ Kelly Fielder
                                  Kelly Fielder, President and Principal
                                  Financial Officer